Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (335)	10/27/2006 7:16:26 PM
From: aladin	Read Replies (1) \| Respond to of 370

I think they may be on to something here, but anything with experimental drugs has ups and downs. I have personal experience with Cloretazine - my wife was involved in a Phase 2 trial for a recurrent anaplastic astrocytoma (Grade 3 brain tumor). This was a last ditch effort to save her life and showed great promise. At 3 months her tumor was over 75% reduced and we were ecstatic - however she then developed a serious lung infection as a result of her treatments (now maybe not all Cloretazine - she had been in 5 other studies over the previous 5 years) - and had to suspend treatment. The tumor came back very strong and we lost her this past April. However, it did make a dramatic impact and I will always wonder if it had been available earlier if her results may have been better.